Drucken
Artikel, Notizen und Markierungen werden geladen... Bitte um etwas Geduld.

Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).

Art. 29 Changes

1 Sig­ni­fic­ant changes to an au­thor­ised clin­ic­al tri­al must be au­thor­ised by the eth­ics com­mit­tee be­fore be­ing im­ple­men­ted. Ex­empt from this re­quire­ment are meas­ures which have to be taken im­me­di­ately in or­der to pro­tect the par­ti­cipants.

2 The in­vest­ig­at­or shall sub­mit to the eth­ics com­mit­tee any ap­plic­a­tion doc­u­ments spe­cified in An­nex 3 which are af­fected by the change. At the same time, the in­vest­ig­at­or shall provide in­form­a­tion on the reas­ons for the change.

3 The fol­low­ing are con­sidered to be sig­ni­fic­ant changes:

a.
changes af­fect­ing the par­ti­cipants’ safety and health, or their rights and ob­lig­a­tions;
b.
changes to the pro­tocol, and in par­tic­u­lar changes based on new sci­entif­ic know­ledge which con­cern the tri­al design, the meth­od of in­vest­ig­a­tion, the en­d­points or the form of stat­ist­ic­al ana­lys­is;
c.
a change of tri­al site, or con­duct­ing the clin­ic­al tri­al at an ad­di­tion­al site; or
d.
a change of spon­sor, co­ordin­at­ing in­vest­ig­at­or or in­vest­ig­at­or re­spons­ible at a tri­al site.

4 The eth­ics com­mit­tee shall reach a de­cision on sig­ni­fic­ant changes with­in 30 days. Art­icle 26 ap­plies mu­tatis mutandis.

5 If a site at which a clin­ic­al tri­al is to be ad­di­tion­ally con­duc­ted does not lie with­in the re­spons­ib­il­ity of the eth­ics com­mit­tee which gran­ted au­thor­isa­tion, the pro­ced­ure is gov­erned by Art­icle 27mu­tatis mutandis.

6 Oth­er changes must be no­ti­fied to the eth­ics com­mit­tee in the an­nu­al safety re­port spe­cified in Art­icle 43.